Neuberger Berman Group LLC Guardant Health, Inc. Transaction History

Neuberger Berman Group LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$43.66 - $61.0 $214,676 - $299,937	4,917 Added 48.17%	15,124 $814,000
Q2 2022 Aug 15, 2022	SELL	$28.82 - $77.35 $2.38 Million - $6.38 Million	-82,493 Reduced 88.99%	10,207 $411,000
Q1 2022 May 13, 2022	BUY	$48.25 - $100.49 $358,931 - $747,545	7,439 Added 8.72%	92,700 $5.92 Million
Q4 2021 Feb 11, 2022	BUY	$88.71 - $120.43 $892,777 - $1.21 Million	10,064 Added 13.38%	85,261 $8.07 Million
Q3 2021 Nov 12, 2021	BUY	$98.77 - $132.17 $1.63 Million - $2.19 Million	16,542 Added 28.2%	75,197 $8.94 Million
Q2 2021 Aug 13, 2021	BUY	$109.77 - $165.68 $155,214 - $234,271	1,414 Added 2.47%	58,655 $6.9 Million
Q1 2021 May 13, 2021	BUY	$127.04 - $179.1 $591,752 - $834,247	4,658 Added 8.86%	57,241 $8.28 Million
Q4 2020 Feb 10, 2021	BUY	$99.96 - $135.93 $1.45 Million - $1.98 Million	14,540 Added 38.22%	52,583 $6.44 Million
Q3 2020 Nov 12, 2020	SELL	$80.32 - $111.8 $1.39 Million - $1.93 Million	-17,303 Reduced 31.26%	38,043 $4.25 Million
Q2 2020 Aug 13, 2020	BUY	$60.49 - $97.5 $403,770 - $650,812	6,675 Added 13.71%	55,346 $4.4 Million
Q1 2020 May 14, 2020	BUY	$59.04 - $88.81 $723,653 - $1.09 Million	12,257 Added 33.66%	48,671 $3.39 Million
Q4 2019 Feb 12, 2020	SELL	$59.49 - $82.78 $5.72 Million - $7.95 Million	-96,088 Reduced 72.52%	36,414 $2.85 Million
Q3 2019 Nov 13, 2019	BUY	$62.59 - $110.3 $236,840 - $417,375	3,784 Added 2.94%	132,502 $8.46 Million
Q2 2019 Aug 13, 2019	BUY	$63.94 - $91.11 $8.23 Million - $11.7 Million	128,718 New	128,718 $11.1 Million

323

127M

844K

2.38M

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $3.34B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

Stay updated on Neuberger Berman Group LLC with notifications on news.